61/99US=4 / Câncer
Silla L, Bittencourt R. Mieloma múltiplo. In: Guimarães JLM, Rosa DD. Rotinas em oncologia. Porto Alegre: Artmed, 2008. p. 716-22. ISBN 85-3631168-5.

MIELOMA MULTIPLO. DIAGNOSTICO; MIELOMA MULTIPLO. PATOLOGIA; MIELOMA MULTIPLO. ESTADIAMENTO; MIELOMA MULTIPLO. FATORES DE RISCO; MIELOMA MULTIPLO. PROGNOSTICO; MIELOMA MULTIPLO. TRATAMENTO


62/99US=4 / Câncer
Vinholes J. Bisfosfonatos em metástases ósseas. In: Guimarães JLM, Rosa DD. Rotinas em oncologia. Porto Alegre: Artmed, 2008. p. 897-903. ISBN 85-3631168-5.

METASTASES OSSEAS; BISFOSFONATOS; MIELOMA MULTIPLO; CANCER DE MAMA; CANCER DE PROSTATA


63/99US=64 / Câncer
Heffner LT. Staging in multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 3-7. (Comtemporary Hematology) ISBN 978-1-934115-82-4.

MIELOMA MULTIPLO; TERAPIA-ALVO; MEDICINA TRADUCAO; BIOINFORMATICA; ACIDO TRANS-RETINOICO; GIST; IMATINIB; DASATINIBE; EPIGENETICA; DECITABINA; DETER HIPOTESE CELULAR


64/99US=64 / Câncer
Langston AA, Francis D. Epidemiology of multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 9-22. (Comtemporary Hematology) ISBN 978-1-934115-82-4.

EPIDEMIOLOGIA; MIELOMA MULTIPLO


65/99US=64 / Câncer
Buadi FK, Rajkumar SV. Thalidomide: induction therapy. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 229-37. (Comtemporary Hematology) ISBN 978-1-934115-82-4.

TALIDOMIDA; TERAPIA DE INDUCAO; MIELOMA MULTIPLO; CLONAL DE CELULAS ESTAMINAIS


66/99US=64 / Câncer
Frost P, Lichtenstein A. The mammalian target of rapamycin and multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 323-30. (Comtemporary Hematology) ISBN 978-1-934115-82-4.

RAPAMICINA EM MAMIFEROS; MIELOMA MULTIPLO; CELULAS EUCARIOTICAS; IMUNO-HISTOQUIMICA


67/99US=64 / Câncer
Jiménez-Zepeda VH, Stewart AK. Fibroblast growth, factor receptor 3 and multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 365-78. (Comtemporary Hematology) ISBN 978-1-934115-82-4.

CRESCIMENTO DE FIBROBLASTOS; RECEPTOR DO FACTOR DE 3; MIELOMA MULTIPLO; TRANSLOCACOES CROMOSSOMICAS


68/99US=64 / Câncer
Hideshima T. Histone deacetylase inhibitors in multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 379-92. (Comtemporary Hematology) ISBN 978-1-934115-82-4.

MIELOMA MULTIPLO


69/99US=64 / Câncer
Mollinedo F. Death receptors in multiple myeloma and therapeutic opportunities. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 393-419. (Comtemporary Hematology) ISBN 978-1-934115-82-4.

RECEPTORES DE MORTE EM MIELOMA MULTIPLO; MIELOMA MULTIPLO


70/99US=64 / Câncer
Mark TM, Pearse RN. Pathophysiology of bone disease in multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 435-54. (Comtemporary Hematology) ISBN 978-1-934115-82-4.

DOENCA OSSEA DO MIELOMA MULTIPLO. FISIOPATOLOGIA; MIELOMA MULTIPLO; MALIGNIDADE DE CELULAS PLASMATICAS; CRESCIMENTO DA MEDULA OSSEA


71/99US=69 / Câncer
Zhou Y, Alexanian R, Wang M. Targeted therapy in multiple myeloma. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 213-36. ISBN 978-1-60327-423-4.

TERAPIA-ALVO; MIELOMA MULTIPLO; PATOGENESE MOLECULAR; MICROAMBIENTE


72/99US=84-A / Biol/Mol
Yasui H, Hideshima T, Anderson KC. Transformig growth factor-B in developing and advanced cancers: inhibition of TGF-B signaling in multiple myeloma and its bone marrow microenvironment. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 219-27. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

TGF-B; IL-6; VEGF; TGF-B RECEPTOR TIPO I; TBRI; MIELOMA MULTIPLO; MICROAMBIENTE DA MEDULA OSSEA; FATOR TRANSFORMADOR DE CRESCIMENTO; FACTOR DE CRESCIMENTO ENDOTELIAL VASCULAR; INIBIDOR DE QUINASE SD-208


73/99US=84-A / Biol/Mol
Hsu FJ, Teicher BA, McPherson JM. Development of inhibitors of transforming growth factor-B signaling for therapy: rationale for anti-TGF-B antibody therapy in oncology. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 757-74. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0.

FACTOR DE CRESCIMENTO TRANSFORMANTE-B; IMUNOSSUPRESSAO; METASTASE OSSEA; CARCINOMA DE CELULAS RENAIS; MELANOMA; CANCER DE MAMA; HORMONAL DO CANCER DA PROSTATA REFRATARIOS; CANCER DE PANCREAS; MIELOMA MULTIPLO; LINFOMA DE NAO-HOGGKIN; BIOMARCADORES


74/99US=86 / Biol/Mol
Chauhan D, Hideshima T, Anderson KC. Targeting proteasomes as therapy in multiple myeloma. In: Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. New York: Springer, 2008. p. 251-60. (Advances in Experimental Medicina and Biology, 615) ISBN 978-1-4020-6553-8.

PROTEOSOMAS; SEGMENTACAO; TERAPIA; MIELOMA MULTIPLO; APOPTOSE; RESISTENCIA A DROGA; BORTEZOMIBE


75/99US=111-A / Câncer
Gribben JG. Management of haematological malignancies. In: Alison MR. The cancer handbook. 2nd ed. New Jersey: John Wiley & Sons, 2007. p. 1392-409. ISBN 978-0-470-01852-1.

CANCER. TERAPIA; DOENCAS MALIGNAS HEMATOLOGICAS; LEUCEMIA AGUDA; LEUCEMIA LINFOBLASTICA AGUDA; LEUCEMIA LINFOCITICA CRONICA; LINFOMA NAO HODGKIN; LINFOMA DE CELULAS B; LINFOMA HODGKIN; MIELOMA MULTIPLO; GAMOPATIA MONOCLONAL


76/99US=71 / Câncer
Chiari AP, Ribeiro RA, Guimarães RC, Oliveira VA, Stephani SD, Sales RMD, Lima VS, Andrade CJC, Lima GPF. Cuidados suportivos: uso clínico dos bisfosfonatos. In: Sociedade Brasileira de Oncologia Clínica. Manuais de condutas da Sociedade Brasileira de Oncologia Clínica. Belo Horizonte: SBOC, 2007. p. 253-60.

BISFOSFONATOS. USO TERAPEUTICO; MIELOMA MULTIPLO; CANCER DE PROSTATA; CANCER DE MAMA; BISFOSFONATOS. COMPLICACOES


77/99US=77-J / Câncer
Nakagawa SA, Chung WT. Câncer ósseo e metastático. In: Lopes A, Chammas R, Iyeyasu H. Oncologia para a graduação. 3ª ed. São Paulo: Lemar, 2013. p. 501-7. ISBN 8-5866523-7-0.

CANCER OSSEO; TUMORES MUSCULOESQUELETICOS; OSTEOSSARCOMA; TUMOR DE EWING; MIELOMA MULTIPLO; METASTASE OSSEA; CONDROSSARCOMA


78/99US=77-J / Câncer
Braga WMT, Almeida MSS, Colleoni GWB. Mieloma múltiplo. In: Lopes A, Chammas R, Iyeyasu H. Oncologia para a graduação. 3ª ed. São Paulo: Lemar, 2013. p. 559-66. ISBN 8-5866523-7-0.

MIELOMA MULTIPLO. DIAGNOSTICO; MIELOMA MULTIPLO. ESTADIAMENTO; MIELOMA MULTIPLO. PROGNOSTICO; MIELOMA MULTIPLO. TERAPIA; TALIDOMIDA; LENALIDOMIDA; BORTEZOMIBE; BISFOSFONATOS


79/99US=104 / Câncer
Miguel JFS, Gutérrez NC. Hematologic malignancies: multiple myeloma. In: Gospodarowicz MK, Sullivan BO, Sobin LH. Prognostic factors in cancer. New Jersey: John Wiley & Sons, 2006. p. 301-4. (International Union Against Cancer) ISBN 978-0-470-03801-2.

MALIGNIDADES HEMATOLOGICAS; MIELOMA MULTIPLO


80/99US=4 / Ortopedia
Heck RK Jr. Tumores malignos do osso. In: Canale ST. Cirurgia ortopédica de Campbell. 10ª ed. Barueri: Manole, 2006. p. 827-58. ISBN 85-204-2273-x.

ORTOPEDIA; TUMORES OSSEOS MALIGNOS; OSTEOSSARCOMA; CONDROSSARCOMA; SARCOMA DE EWING; CORDOMA; ADAMANTINOMA; TUMORES VASCULARES MALIGNOS; HISTIOCITOMA FIBROSO MALIGNO; FIBROSSARCOMA; MIELOMA MULTIPLO; PLASMOCITOMA; LINFOMA; CARCINOMA METASTATICO


Primeira | Anterior | Próxima | Última